Drug Interaction:
Mutually increased levels effects when used with drugs extensively metabolised by CYP3A Reduced levels/efects of methadone
Indication:
Neviramine Extended release tablet 400mg (Additional Strength)
Indication-
For use in combination with other anti-retroviral agents for treatment of
HIV- 1 infection in adults
Approved by FDA on 01-07-2014 (Ref- FDA approved List- 2014)
HIV infection
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Nevirapine Anti HIV 06-03-2000
2.Neviramine tablet 50mg 18-07-2009
For oral suspn.
For the treatment of HIV infection in combination with other Anti-retroviral
agents
3.Neviramine Extended release tablet 18-07-2009
400mg (Addl.Stgth.)
For use in Combination with other Retroviral agents for the treatment
of HIV- Infection in adults
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Nevirapine HIV/AIDS Boehringer 22-11-2011
Ingelheim
Adverse Reaction:
Skin rash, nausea,vomiting, headache, abnormal LFT, fatigue, diarrhoea abdominal pain severe & life threatening hepatotoxic and skin reactions
Contra-Indications:
Hypersenstivity Lactation Severe hepatic impairment
Special precaution-
Pregnancy- interrupt treatment if severe hepatotoxicity or life threatening skin reactions develop. Renal or hepatic insufficiency Monitor liver function periodically
Dosages/ Overdosage Etc:
HIV infection
Dosage-
combined 200mg once daily for 1st 14 days increase to 200mg bid if rash does not develop interupting treatment for > 7 days, necessiciate reintroduction at lower dose for 1st 14 days
Child- combined 2mth - 8yr- 4mg/kg once daily for 1st 14days increase to 7mg/kg bid if no rash is present 8-16yr- 4mg/kg once daily for 14 days followed by 4mg/kg bid max- 400mg daily,interupting for > 7days necissiciate reintroduction at a lower dose for the 1st 14 days
Pregnancy and lactation:
Use contraindicated. Observe caution
Manufacturer Details